A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

NCT05358886 | Completed Phase 3 DMC FDA Drug

• 1 other identifier: BPN14770-CNS-301
• Study Type: interventional
• Target: 171
• Locations: 1 country
• Sites: 17

Brief Summary

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome

Conditions

Fragile X Syndrome

Keywords

FXS

Outcome Measures

Primary Outcomes (1)

• National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC)

  National Institutes of Health Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains.

  13 Weeks

Secondary Outcomes (8)

• Numerical rating scale (NRS) scores based on subject-specific behaviors vs baseline

  13 Weeks

• Caregiver Global Impression of Improvement (CaGI-I)

  13 Weeks

• Clinical Global Impression Improvement (CGI-I) for - Investigator

  13 Weeks

• Vineland-3 Adaptive Behavior Scale (Vineland-3)

  13 Weeks

• Verbal Knowledge test from the Stanford-Binet (ed 5) (SB-5)IQ

  13 Weeks

Study Arms (2)

Study Drug

ACTIVE COMPARATOR

25mg BID BPN14770

Drug: BPN14770/ zatolmilast

Placebo

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

BPN14770/ zatolmilast DRUG

25mg BID BPN14770

Study Drug

Placebo DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Male
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male subject aged 18 to 45 years at screening visit.
• Subject has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1)mutation (≥200 CGG repetitions).
• Subject is able to swallow capsules.
• Current treatment with ≤3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for the treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications.
• Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks prior to screening and must remain stable during the period between screening and the commencement of the study treatment.
• Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to screening and must remain stable during the period between screening and commencement of the study treatment.
• Subjects with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure free for 3 months preceding screening or must be seizure free for 2 years if not currently receiving anti-epileptics.
• Subject must be willing to practice barrier methods of contraception while on the study if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.
• Subject has a parent, legal authorized guardian, or consistent caregiver.
• Subject and caregiver are able to attend the clinic regularly and reliably.
• If subject is his own legal guardian, he is able to understand and sign informed consent to participate in the study.
• For subjects who are not their own legal guardian, subject's parent/legally authorized guardian is able to understand and sign an informed consent form for their child to participate in the study.
• If subject is not his own legal guardian, subject must provide assent for participation in the study if he has the cognitive ability to do so.

You may not qualify if:

• Inability to successfully complete the NIH-TCB picture vocabulary and oral reading assessments at screening and baseline. The ability to complete the NIH-TBC oral reading and picture vocabulary subtest at baseline is defined as the ability to complete both subtests, with (1) confirmation from the clinician administering that the test administrations are valid (noted on the administration form) and (2) generation of valid test scores for each test.
• History of or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the subject at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study treatment.
• a. Common conditions such as mild hypertension, etc. are allowed per the principal investigator's judgement as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization.
• Renal impairment, defined as serum creatinine \> 1.25 × ULN at screening
• Hepatic impairment, defined as ALT or AST elevation \> 2 × ULN at screening. Note: LFTs may be repeated after 1 week to evaluate return to acceptable limits; if LFTs remain elevated, the subject is ineligible to participate.
• Clinically significant abnormalities, in the investigator's judgement, in safety laboratory tests, vital signs, or ECG, as measured during screening.
• History of substance abuse within the past year, according to investigator assessment.
• Positive COVID-19 test during screening.
• Significant hearing or visual impairment that may affect the subject's ability to complete the test procedures.
• Concurrent major psychiatric condition (eg, major depressive disorder, schizophrenia, or bipolar disorder) as diagnosed by the investigator. Subjects with the additional diagnosis of autism spectrum disorder or anxiety disorder will be allowed.
• Subject has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
• Subject is planning to commence psychotherapy or cognitive behavior therapy during the period of the study or had begun psychotherapy or cognitive behavior therapy within 4 weeks prior to screening.
• Subject is an immediate family member of anyone employed by the sponsor, investigator, or study staff.
• Subject has a body mass index of less than 18 kg/m2 or greater than 36 kg/m2.
• Subject has participated in another clinical trial within the 30 days preceding Screening

Sponsors & Collaborators

• Tetra Discovery Partners: lead

Study Sites (17)

Amnova Clinical Research

Irvine, California, 92604, United States

Location

Thompson Autism & Neurodevelopment Center - CHOC

Orange, California, 92868, United States

Location

UC Davis Health System

Sacramento, California, 95817, United States

Location

Children's Hospital Colorado

Aurora, Colorado, 80045, United States

Location

University of Miami

Miami, Florida, 33136, United States

Location

Emory University School of Medicine

Atlanta, Georgia, 30322, United States

Location

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Kennedy Krieger Institute

Baltimore, Maryland, 21205, United States

Location

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location

University of Massachusetts Medical School

Worcester, Massachusetts, 01655, United States

Location

Icahn School of Medicine at Mount Sinai Hospital

New York, New York, 10029, United States

Location

Cincinnati Childrens Hospital Medical Center

Cincinnati, Ohio, 45229, United States

Location

Suburban Research Associates

Media, Pennsylvania, 19063, United States

Location

Clinic for Special Children

Strasburg, Pennsylvania, 17579, United States

Location

Greenwood Genetic Center

Greenville, South Carolina, 29605, United States

Location

University of Utah and Primary Childrens Hospital

Salt Lake City, Utah, 84113, United States

Location

MeSH Terms

Conditions

Fragile X Syndrome

Interventions

BPN14770

Condition Hierarchy (Ancestors)

X-Linked Intellectual Disability; Intellectual Disability; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Sex Chromosome Disorders; Chromosome Disorders; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Heredodegenerative Disorders, Nervous System

Study Officials

• Elizabeth Berry-Kravis, MD

  Rush Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2022
• First Posted: May 3, 2022
• Study Start: November 1, 2022
• Primary Completion: July 18, 2025
• Study Completion: July 18, 2025
• Last Updated: July 23, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (17)